white-paper
A patient may have pre-existing antibodies (PEXA) to a therapeutic, which can impact the immune response to the drug in question. In this paper, we discuss the nature of PEXAs, how they can be detected and characterized, and how sponsors should proceed when they are present.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.